country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-10893

Copy Link Print Information

TNK-651

TNK-651 is a non-nucleoside HIV-1 reverse transcriptase inhibitor. TNK-651 exhibits inhibitory effects on both the HIV-1 SF33 strain and the NNRTI-resistant HIV-1 A17 strain. TNK-651 can be used for the study of HIV-1 infection.

For research use only. We do not sell to patients.

CAS No.: 175739-42-1
Formula: C₂₂H₂₄N₂O₃
Molecular Weight:364.44

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

TNK-651 Chemical Structure

CAS No.: 175739-42-1

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CEM-SS	CC₅₀	>20 μM Compound: 3, TNK-651	Cytotoxicity in human CEM-SS cells after 6 days by MTS assay Cytotoxicity in human CEM-SS cells after 6 days by MTS assay	[PMID: 21499541]
CEM-SS	EC₅₀	0.013 μM Compound: 3, TNK-651	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by MTS assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by MTS assay	[PMID: 21499541]
MT4	CC₅₀	84.596 μM Compound: 2, TNK-651	Cytotoxicity against human MT4 cells after 3 days by XTT assay Cytotoxicity against human MT4 cells after 3 days by XTT assay	[PMID: 23540737]
MT4	CC₅₀	84.6 μM Compound: 18, TNK-651	Cytotoxicity against human MT4 cells after 3 days by XTT assay Cytotoxicity against human MT4 cells after 3 days by XTT assay	[PMID: 22283377]
MT4	EC₅₀	>10 μM Compound: 18, TNK-651	Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	[PMID: 22283377]
MT4	EC₅₀	>10 μM Compound: 2, TNK-651	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	>10 μM Compound: 2, TNK-651	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	0.022 μM Compound: 18, TNK-651	Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	[PMID: 22283377]
MT4	EC₅₀	0.022 μM Compound: 2, TNK-651	Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	2.398 μM Compound: 2, TNK-651	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
PBMC	CC₅₀	>10 μM Compound: 4b, ZW-IV-55-1, TNK651	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 17608468]
TZM	CC₅₀	65.812 μM Compound: 2, TNK-651	Cytotoxicity against human TZM-bl cells Cytotoxicity against human TZM-bl cells	[PMID: 23540737]

Chemical Information

CAS No. 175739-42-1
Molecular Weight 364.44
Formula C₂₂H₂₄N₂O₃
SMILES

O=C1C(C(C)C)=C(CC2=CC=CC=C2)N(COCC3=CC=CC=C3)C(N1)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (269 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang X, et al. Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote